| Human immunodeficiency virus I infection
Complera vs Odefsey
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Complera vs Odefsey with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOdefsey has a higher rate of injection site reactions vs Complera based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Odefsey but not Complera, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Complera
Odefsey
At A Glance
Oral
Once daily
NRTI/NNRTI fixed-dose combination
Oral
Once daily
NRTI + NNRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet orally once daily with food for adults and pediatric patients weighing at least 35 kg; not recommended in patients with estimated creatinine clearance below 50 mL/min.
Pregnancy One tablet once daily may be continued in virologically suppressed patients (HIV-1 RNA less than 50 copies/mL); monitor viral load closely due to lower rilpivirine exposures during pregnancy.
Rifabutin coadministration Add one additional 25 mg rilpivirine (Edurant) tablet once daily with a meal for the duration of rifabutin coadministration.
Human immunodeficiency virus I infection One tablet (emtricitabine 200 mg, rilpivirine 25 mg, tenofovir alafenamide 25 mg) orally once daily with a meal
Contraindications
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with dexamethasone (systemic, more than a single dose)
- Coadministration with St John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
- Coadministration with carbamazepine
- Coadministration with oxcarbazepine
- Coadministration with phenobarbital
- Coadministration with phenytoin
- Coadministration with rifampin
- Coadministration with rifapentine
- Coadministration with dexamethasone (more than a single dose)
- Coadministration with St. John's wort
- Coadministration with proton pump inhibitors
Adverse Reactions
Most common (>=2%) Depressive disorders, headache, insomnia, abnormal dreams, dizziness, nausea, rash
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, bone loss and mineralization defects, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight gain, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, allergic reaction including angioedema, lactic acidosis, pancreatitis, rhabdomyolysis, osteomalacia, acute renal failure, Fanconi syndrome
Most common (>=2%) Headache, sleep disturbances
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight increased, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Pharmacology
COMPLERA is a fixed-dose combination antiretroviral containing emtricitabine (nucleoside reverse transcriptase inhibitor), rilpivirine (non-nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor); each component inhibits HIV-1 reverse transcriptase through distinct mechanisms to suppress viral replication.
Odefsey is a fixed-dose combination of emtricitabine (an NRTI that inhibits HIV-1 reverse transcriptase by chain termination), rilpivirine (an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase), and tenofovir alafenamide (a prodrug that is converted to tenofovir, an NRTI inhibiting HIV-1 reverse transcriptase by chain termination).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Complera
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Odefsey
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Complera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Odefsey
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Complera
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Odefsey
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CompleraView full Complera profile
OdefseyView full Odefsey profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.